Spotlight
Topics
DI Executive
Subscribe
- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
3T MRI-Compatible Small Body Array Gets FDA Nod
Featuring a lightweight body contouring design, the Small Body Array reportedly facilitates optimal signal-to-noise ratio (SNR) and between 10 and 40 percent faster throughput.
The Food and Drug Administration (FDA) has granted 510(k) clearance for a 3T magnetic resonance imaging (MRI)-compatible Small Body Array, which emphasizes a body contouring design and coils that are 80 percent lighter than conventional coils.
The body-hugging design of the Small Body Array adapts to a wide range of patient anatomies and sizes, according to InkSpace Imaging, the developer of the Small Body Array. The company emphasized that the Small Body Array provides optimal signal-to-noise ration (SNR), which improves detection of subtle abnormalities that may be missed by conventional coils.
In addition to increased patient comfort, InkSpace Imaging said the Small Body Array offers high coil element density, which helps streamline MRI acquisition. The company noted that the coils with the Small Body Array allow up to 40 percent faster throughput.
“The FDA clearance of InkSpace Imaging's Small Body Array marks a pivotal moment in MRI technology advancement. Our suite of MR coils is a game-changer, offering total freedom in coil positioning and handling,” noted Peter Fischer, the CEO of InkSpace Imaging. “What's truly impressive is how our thin flexible coil contours to each patient's body, offering comfort while enhancing image quality. It's a win-win for patients and health-care providers alike."
InkSpace Imaging said the Small Body Array is compatible with the Magnetom Skyra (Siemens Healthineers) and Magnetom Vida (Siemens Healthineers) series 3T MRI scanners.
Recent Videos
Related Content
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Article
Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
